weight control therapies offered by VIVUS ( VVUS ) and Arena Pharmaceuticals ( ARNA ..... approvals for Qsymia and Belviq, from VIVUS and Arena respectively, to be a ..... has transpired over the past year . VIVUS and Qsymia Qsymia was the first treatment
have followed closely. Background Vivus ( VVUS ) is a biotechnology company that ..... frustrating approval process for Qsymia, Vivus finally achieved approval in 2012 ..... approve a new weight loss drug and made Vivus jump through some pretty difficult
By Spencer Osborne : Arena Pharmaceuticals ( ARNA ) reported earnings yesterday. Today the news and follow-through will be on prescription sales. As most investors already know, Arena posted a loss for Q4. The revenue from Arena's share of Belviq sales was about $2.4 million. One thing that the ...
By Spencer Osborne : It may not have made me very popular with Arena ( ARNA ) retail longs, but my article this morning spelled out that the sales numbers were not likely to impress the Street when Arena announced its quarterly results. After hours, Arena is trading down about 4% to around $6.50.
setting any records. Competitor Vivus , with Qsymia saw sales numbers that ..... recent bullishness. For perspective, Vivus ( VVUS ) announced Q4 net sales of about ..... 6 million for the same quarter. Vivus keeps all of the net sales of its
the United States and playing a bit of catch-up with Vivus ( VVUS ) and Arena ( ARNA ) which already have drugs approved ..... it is currently perceived as having a lead in Europe. Vivus 's Qsymia suffered a rejection across the pond, and
CBAK +20% . SNSS +18% . OESX +17% . AVID +17% . TSLA +17% . Top 10 Losers: RP -23% . EVRY -19% . JONE -17% . PERY -17% . CCCL -13% . RBPAA -13% . FSI -12% . VVUS -12% . MVIS -12% . LMOS -12% . Post your comment!
Gainers: DARA +31% . IMUC +24% . LTRX +18% . MSO +14% . ZU +11% . VSI +10% . AVID +9% . CARA +8% . BCRX +7% . XOMA +7% . CLDN +6% Losers: RP -24% . ODP -17% . VVUS -13% . AINV -6% . WPCS -5% . Post your comment!
Vivus ( VVUS ) slumps 13.9% to $5.81 despite the ..... time licensing payment of $34.8M for Vivus ' erectile dysfunction drug. Sales of anti ..... earlier. Carr reiterates his Hold rating on Vivus , although BofA cuts its rating to Underperform
By Spencer Osborne : Vivus ( VVUS ), best known for its anti-obesity ..... Thus, while the headline says that Vivus beat the street, it really only did ..... have been about $0.51 per share. Vivus announced that sales of the anti-obesity